Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 118

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 118
---
iture on or prior to 11:59 p.m. on June 30, 2025, or such later time and date as may be agreed among the parties under the terms of the Divestiture Agreement (the “Termination Date”) and (2) “Company Material Adverse Effect” means any Effect that, individually or taken together with all other Effects, (A) has had or would reasonably be expected to have a material adverse effect on the business, financial condition or results of operations of Aadi Sub, taken as a whole, or (B) prevents or would reasonably be expected to prevent Aadi Sub from consummating the Divestiture on or prior to the Termination Date. However, the parties have agreed that none of the following Effects will be deemed to be or constitute a Company Material Adverse Effect or will be taken into account when determining whether there has been or would reasonably be expected to occur a Company Material Adverse Effect:

| • |     | general economic conditions in the United States or any other country or region in the world, or changes in 
 conditions in the global economy generally (except in each case to the extent that such                     |

- 74 -

| Effect has had a disproportionate adverse effect on Aadi Sub relative to other similarly situated companies operating in the industries in which Aadi Sub conducts business, in which case only the                                               
 incremental disproportionate adverse impact of such Effect on Aadi Sub as compared to the impact of such Effect on such other similarly situated companies may be taken into account in determining whether a Company Material Adverse Effect has 
 occurred);                                                                                                                                                                                                                                        |

| • |     | conditions in the financial markets, credit markets or capital markets in the United States or any other country                                                                                                                                          
 or region in the world, including (1) monetary policy, interest rates or credit ratings in the United States or any other country or region of the world, (2) exchange rates for the currencies of any country, or (3) any suspension of                  
 trading in securities (whether equity, debt, derivative or hybrid securities) generally on any securities exchange or over-the-counter market operating in the United                                                                                     
 States or any other country or region in the world (except in each case to the extent that such Effect has had a disproportionate adverse effect on Aadi Sub relative to other similarly situated companies operating in the industries in which Aadi Sub 
 conducts business, in which case only the incremental disproportionate adverse impact of such Effect on Aadi Sub as compared to the impact of such Effect on such other similarly